Biologic therapy in idiopathic inflammatory myopathy

Albert Selva-O'Callaghan, Manel Ramos Casals, Josep M. Grau Junyent

Research output: Contribution to journalReview articleResearchpeer-review

1 Citation (Scopus)


The aim of this article is to study the evidence-based knowledge related to the use of biological therapies in patients diagnosed with idiopathic inflammatory myopathy (dermatomyositis, polymyositis and inclusion body myositis). In this review the leading published studies related to the use of biological therapy in patients with myositis are analysed; mainly those with high methodological standards, that means randomized and controlled studies. Methodological drawbacks due to the rarity and heterogeneity of these complex diseases are also addressed. Up to now is not possible to ascertain the biologics as a recommended therapy in patients with myositis, at least based in the current evidence-based knowledge, although it can not be neglected as a therapeutic option in some clinical situations, taking into account the scarce of effective treatments in those patients, especially in refractory myositis. Future studies probably will help to better define the role of biological therapies in patients with idiopathic inflammatory myopathy. © 2013 Elsevier Espan a, S.L.U. All rights reserved.
Original languageEnglish
Pages (from-to)275-280
JournalMedicina Clinica
Issue number6
Publication statusPublished - 1 Jan 2014


  • Biologic therapy
  • Idiopathic inflammatory myopathy
  • Myositis


Dive into the research topics of 'Biologic therapy in idiopathic inflammatory myopathy'. Together they form a unique fingerprint.

Cite this